公开(公告)号：US20220298243A1

公开(公告)日：2022-09-22

申请号：US17715875

申请日：2022-04-07

Applicant: Bristol-Myers Squibb Company ,  Seattle Genetics, Inc.

Inventor： Benedetto FARSACI ,  Neil JOSEPHSON ,  Anthony CAO ,  Ryan HEISER

IPC: C07K16/28 ,  A61P35/00

Abstract: This disclosure provides methods for treating a tumor in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD30 antibody. In some embodiments, the tumor is derived from a lymphoma (e.g., a Hodgkin lymphoma or a non-Hodgkin lymphoma). In certain embodiments, the anti-CD30 antibody is an antibody-drug conjugate, e.g., brentuximab vedotin.

公开(公告)号：US11325980B2

公开(公告)日：2022-05-10

申请号：US16085511

申请日：2017-03-15

Applicant: SEATTLE GENETICS, INC.

Inventor： Django Sussman ,  Fu Li ,  Ana Kostic

IPC: A61K31/337 ,  A61K31/555 ,  A61K31/704 ,  C07K16/30 ,  A61K39/395 ,  A61K47/68 ,  C07K16/28 ,  A61K9/00 ,  A61K39/00

Abstract: The invention provides methods of treating a subject having or at risk of cancer by administering a LIV-1 antibody drug conjugate and a chemotherapeutic.

公开(公告)号：US11229708B2

公开(公告)日：2022-01-25

申请号：US15781244

申请日：2016-12-02

Applicant: SEATTLE GENETICS, INC.

Inventor： Patrick J. Burke ,  Joel Courter

IPC: A61K47/55 ,  A61K47/68 ,  C07K5/02 ,  A61K47/65 ,  A61K47/64 ,  A61P35/02 ,  A61K9/00 ,  A61K9/08 ,  A61K31/454 ,  A61K38/05 ,  A61K38/06 ,  A61K38/00

Abstract: Compounds and compositions are disclosed in which a quaternized drug unit is linked to a targeting ligand unit from which a tertiary amine-containing drug is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease using the compounds and compositions of the invention are also disclosed.

公开(公告)号：US20210221901A1

公开(公告)日：2021-07-22

申请号：US16755403

申请日：2018-10-11

Applicant: Seattle Genetics, Inc.

Inventor： Thomas Manley ,  Neil Josephson

IPC: C07K16/28 ,  A61K31/4164 ,  A61K31/475 ,  A61K31/704 ,  A61P35/02 ,  A61K47/68

Abstract: The present disclosure, relates, in general to methods for improving adverse events in subjects receiving treatment with an anti-CD30 antibody drug conjugate, optionally also receiving accompanying chemotherapy. Adverse events include peripheral neuropathy and neutropenia.

公开(公告)号：US10912842B2

公开(公告)日：2021-02-09

申请号：US15735738

申请日：2016-06-09

Applicant: SEATTLE GENETICS, INC.

Inventor： May Kung Sutherland ,  Lori Westendorf ,  Django Sussman

IPC: A61K47/68 ,  C07K16/28 ,  A61K31/5513 ,  A61K31/5517 ,  A61P35/02 ,  A61P35/00 ,  C07K16/30 ,  A61K39/00

Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD123 and conjugates thereof.

公开(公告)号：US20210017213A1

公开(公告)日：2021-01-21

申请号：US16850353

申请日：2020-04-16

Applicant: Seattle Genetics, Inc.

Inventor： Ana Paula Galvao da Silva ,  Mai Zhang ,  Darius Ghaderi ,  Julie DeSander ,  Jeffrey Behrens ,  Jillian M. Prendergast

IPC: C07H15/04 ,  G01N33/574 ,  G01N33/68 ,  C40B40/12

Abstract: The invention provides methods and tools, for example, glycan arrays, for the analysis of glycans and anti-glycan antibodies. Embodiments of the invention may be used to detect proteins, antibodies, diseases and/or pathogenic agents. In other embodiments, methods of the invention are used to develop or optimize arrays and antibodies.

公开(公告)号：US10787514B2

公开(公告)日：2020-09-29

申请号：US15411947

申请日：2017-01-20

Applicant: SEATTLE GENETICS, INC.

Inventor： May Kung Sutherland ,  Maureen Ryan ,  Django Sussman ,  Patrick Burke ,  Scott Jeffrey

IPC: C07K16/28 ,  A61K39/00 ,  A61K31/551 ,  A61K47/68

Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically hind to CD33. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting CD33.

公开(公告)号：US20200297864A1

公开(公告)日：2020-09-24

申请号：US16645369

申请日：2018-09-07

Applicant: SEATTLE GENETICS, INC.

Inventor： Kun-Liang Wu ,  Qingwu Jin ,  Wendel Doubleday

IPC: A61K47/68 ,  C07K5/02

Abstract: Improved processes for the preparation of tubulysin compounds, tubulysin drug linker compounds, and their intermediates are disclosed.

公开(公告)号：US20200247902A1

公开(公告)日：2020-08-06

申请号：US16462084

申请日：2017-11-17

Applicant: Seattle Genetics, Inc.

Inventor： Jillian M. Prendergast ,  David A. Eavarone ,  Patricia Rao

IPC: C07K16/30 ,  G01N33/574 ,  A61K47/68 ,  A61P35/00 ,  C07K16/28

Abstract: Methods of detecting, characterizing, and targeting myeloid-derived suppressor cells are disclosed. Some methods include the use of glycan-interacting antibodies, such as anti-STn antibodies. Methods of identifying subjects for treatment with glycan-interacting antibodies are included.

公开(公告)号：US20200222553A1

公开(公告)日：2020-07-16

申请号：US16497133

申请日：2018-03-23

Applicant: SEATTLE GENETICS, INC.

Inventor： Yunyu Mao ,  Philip Moquist ,  Anusuya Choudhury ,  Wendel Doubleday

IPC: A61K47/68 ,  C07H15/26 ,  C07D487/04

Abstract: The present invention provides improved processes for the preparation of drug-linkers with a β-glucuronide cleavable unit, as well as intermediates thereof.